Update in diffuse parenchymal lung disease 2013

American Journal of Respiratory and Critical Care Medicine

Volumn 191, Issue 3, 2015, Pages 270-274

  Rosas, Ivan O ^a,b   Kaminski, Naftali ^c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b LOVELACE RESPIRATORY RESEARCH INSTITUTE   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Genomics; ILD; Immunity; IPF; Personalized medicine

Indexed keywords

ADAPTIVE IMMUNITY; APOPTOSIS; CELL DIFFERENTIATION; DISEASE COURSE; FIBROSING ALVEOLITIS; GENOMICS; HEALTH CARE QUALITY; HUMAN; INNATE IMMUNITY; LUNG ALVEOLUS EPITHELIUM CELL; LUNG FIBROBLAST; NONHUMAN; PERSONALIZED MEDICINE; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; DRUG APPROVAL; FOOD AND DRUG ADMINISTRATION; GENETIC POLYMORPHISM; GENETICS; IDIOPATHIC PULMONARY FIBROSIS; LUNG DISEASES, INTERSTITIAL; PHASE 3 CLINICAL TRIAL (TOPIC); TREATMENT OUTCOME; UNITED STATES;

ENZYME INHIBITOR; INDOLE DERIVATIVE; NINTEDANIB; NONSTEROID ANTIINFLAMMATORY AGENT; PIRFENIDONE; PYRIDONE DERIVATIVE;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CLINICAL TRIALS, PHASE III AS TOPIC; DISEASE PROGRESSION; DRUG APPROVAL; ENZYME INHIBITORS; GENOMICS; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; INDOLES; LUNG DISEASES, INTERSTITIAL; POLYMORPHISM, GENETIC; PYRIDONES; TREATMENT OUTCOME; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84922311555     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201405-0856UP     Document Type: Review

References (23)

1. Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, Cottin V, Flaherty KR, Hansell DM, Inoue Y, et al.; INPULSIS Trial Investigators. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 2014;370:2071-2082.
2. King TE Jr, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, Gorina E, Hopkins PM, Kardatzke D, Lancaster L, et al.; ASCEND Study Group. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 2014;370:2083-2092.
3. Noble PW, Albera C, Bradford WZ, Costabel U, Glassberg MK, Kardatzke D, King TE Jr, Lancaster L, Sahn SA, Szwarcberg J, et al.; CAPACITY Study Group. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet 2011;377:1760-1769.
4. Chowdhury BA. Two FDA drug approvals for idiopathic pulmonary fibrosis (IPF). FDAVoice; 2014 Oct 15 [accessed 2015 Jan 8]. Available from: http://blogs.fda.gov/fdavoice/index.php/2014/10/two-fda-drug-approvals-for-idiopathic-pulmonary-fibrosis-ipf/
5. Noth I, Kaminski N. Idiopathic pulmonary fibrosis: time to get personal? Am J Respir Crit Care Med 2013;188:1392-1394.
6. Rosas IO, Yang IV. The promise of epigenetic therapies in treatment of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2013;187:336-338.
7. Fingerlin TE, Murphy E, Zhang W, Peljto AL, Brown KK, Steele MP, Loyd JE, Cosgrove GP, Lynch D, Groshong S, et al. Genome-wide association study identifies multiple susceptibility loci for pulmonary fibrosis. Nat Genet 2013;45:613-620.
8. Peljto AL, Zhang Y, Fingerlin TE, Ma SF, Garcia JG, Richards TJ, Silveira LJ, Lindell KO, Steele MP, Loyd JE, et al. Association between the MUC5B promoter polymorphism and survival in patients with idiopathic pulmonary fibrosis. JAMA 2013;309:2232-2239.
9. Stock CJ, Sato H, Fonseca C, Banya WA, Molyneaux PL, Adamali H, Russell AM, Denton CP, Abraham DJ, Hansell DM, et al. Mucin 5B promoter polymorphism is associated with idiopathic pulmonary fibrosis but not with development of lung fibrosis in systemic sclerosis or sarcoidosis. Thorax 2013;68:436-441.
10. Hunninghake GM, Hatabu H, Okajima Y, Gao W, Dupuis J, Latourelle JC, Nishino M, Araki T, Zazueta OE, Kurugol S, et al. MUC5B promoter polymorphism and interstitial lung abnormalities. N Engl J Med 2013;368:2192-2200.
11. Noth I, Zhang Y, Ma S-F, Flores C, Barber M, Huang Y, Broderick SM, Wade MS, Hysi P, Scuirba J, et al. Genetic variants associated with idiopathic pulmonary fibrosis susceptibility and mortality: a genome-wide association study. Lancet Respir Med 2013;1:309-317.
12. O'Dwyer DN, Armstrong ME, Trujillo G, Cooke G, Keane MP, Fallon PG, Simpson AJ, Millar AB, McGrath EE, Whyte MK, et al. The Toll-like receptor 3 L412F polymorphism and disease progression in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2013;188:1442-1450.
13. Herazo-Maya JD, Noth I, Duncan SR, Kim S, Ma SF, Tseng GC, Feingold E, Juan-Guardela BM, Richards TJ, Lussier Y, et al. Peripheral blood mononuclear cell gene expression profiles predict poor outcome in idiopathic pulmonary fibrosis. Sci Transl Med 2013;5:205ra136.
14. Tanjore H, Degryse AL, Crossno PF, Xu XC, McConaha ME, Jones BR, Polosukhin VV, Bryant AJ, Cheng DS, Newcomb DC, et al. β-catenin in the alveolar epithelium protects from lung fibrosis after intratracheal bleomycin. Am J Respir Crit Care Med 2013;187:630-639.
15. Gottardi CJ, Königshoff M. Considerations for targeting β-catenin signaling in fibrosis. Am J Respir Crit Care Med 2013;187:566-568.
16. Shi Y, Gochuico BR, Yu G, Tang X, Osorio JC, Fernandez IE, Risquez CF, Patel AS, Shi Y, Wathelet MG, et al. Syndecan-2 exerts antifibrotic effects by promoting caveolin-1-mediated transforming growth factor-β receptor I internalization and inhibiting transforming growth factor-β1 signaling. Am J Respir Crit Care Med 2013;188:831-841.
17. Henderson NC, Arnold TD, Katamura Y, Giacomini MM, Rodriguez JD, McCarty JH, Pellicoro A, Raschperger E, Betsholtz C, Ruminski PG, et al. Targeting of αv integrin identifies a core molecular pathway that regulates fibrosis in several organs. Nat Med 2013;19:1617-1624.
18. Zhou Y, Huang X, Hecker L, Kurundkar D, Kurundkar A, Liu H, Jin TH, Desai L, Bernard K, Thannickal VJ. Inhibition of mechanosensitive signaling in myo fibroblasts ameliorates experimental pulmonary fibrosis. J Clin Invest 2013;123:1096-1108.
19. Rosas IO, Kottmann RM, Sime PJ. New light is shed on the enigmatic origin of the lung myofibroblast. Am J Respir Crit Care Med 2013;188:765-766.
20. Hung C, Linn G, Chow YH, Kobayashi A, Mittelsteadt K, Altemeier WA, Gharib SA, Schnapp LM, Duffield JS. Role of lung pericytes and resident fibroblasts in the pathogenesis of pulmonary fibrosis. Am J Respir Crit Care Med 2013;188:820-830.
21. Nakashima T, Liu T, Yu H, Ding L, Ullenbruch M, Hu B, Wu Z, Oguro H, Phan SH. Lung bone marrow-derived hematopoietic progenitor cells enhance pulmonary fibrosis. Am J Respir Crit Care Med 2013;188:976-984.
22. Reilkoff RA, Peng H, Murray LA, Peng X, Russell T, Montgomery R, Feghali-Bostwick C, Shaw A, Homer RJ, Gulati M, et al. Semaphorin 7a+ regulatory T cells are associated with progressive idiopathic pulmonary fibrosis and are implicated in transforming growth factor-β1-induced pulmonary fibrosis. Am J Respir Crit Care Med 2013;187:180-188.
23. Kahloon RA, Xue J, Bhargava A, Csizmadia E, Otterbein L, Kass DJ, Bon J, Soejima M, Levesque MC, Lindell KO, et al. Patients with idiopathic pulmonary fibrosis with antibodies to heat shock protein 70 have poor prognoses. Am J Respir Crit Care Med 2013;187:768-775.